Committee on International Relations U.S. House of Representatives
Henry J. Hyde, Chairman
CONTACT: Sam Stratman, (202) 226-7875, March 16, 2005
For IMMEDIATE Release
Combating Malaria and Tuberculosis
Christopher Smith Schedules Tuesday Hearing on Implementing Proven
Treatment and Eradication Methods
BACKGROUND: The global pandemic of HIV/AIDS is frequently the focus of
high-profile news coverage, but much of the developing world is being
ravaged by two other, relatively unknown, killer diseases: malaria and
tuberculosis (TB). One-third of the world is infected with the TB
bacterium, and it is the leading cause of death for people with HIV/AIDS.
Africa is currently experiencing a TB explosion due in large part to the
AIDS pandemic. Similarly, Malaria is the primary killer of children and
pregnant women in Africa, and one of the top killers in Asia and South
America. Every day about 3,000 children die from the disease worldwide.
Infection rates for malaria dwarf those of HIV/AIDS, and the vast majority
of malaria patients are pregnant women and children living in poverty.
However, both diseases are preventable and curable. A six-month course of
anti-TB drugs costs only $12 and can produce cure rates of up to 95 percent
even in the poorest countries. Malaria, likewise, is inexpensive and easy
to treat, and can be controlled with proven successful methods combining
anti-malarial drugs, bed nets, and use of small, environmentally safe
amounts of insecticide in homes and buildings. In FY 2005, the United
States will provide $2.9 billion in bilateral and multilateral assistance
to fight HIV/AIDS, malaria and tuberculosis. Among the witnesses scheduled
to testify Tuesday is Youssou N?Dour, Senegalese Jazz Musician, Goodwill
Ambassador, and Roll Back Malaria Partnership.
WHAT: Subcommittee Oversight Hearing: Malaria and TB: Implementing Proven
Treatment
and Eradication Methods
Subcommittee on Africa, Global Human Rights and International Operations,
U.S. Rep. Christopher H. Smith (R-NJ), Chairman
WHEN: 2:00 p.m., Tuesday, April 26, 2005
WHERE: Room 2172 Rayburn House Office Building
WITNESSES: Mark Dybul, M.D., Assistant U.S. Global AIDS Coordinator and
Chief Medical Officer, Office of the
U.S. Global AIDS Coordinator, U.S. Department of State;
Michael Miller, Deputy Assistant Administrator, Bureau for Global Health,
U.S. Agency for
International Development;
William Moeller, President and CEO, American Biotech Labs;
Youssou N?Dour, Senegalese Jazz Musician, Goodwill Ambassador, Roll Back
Malaria Partnership; and
Paul Nunn, M.D., Coordinator, TB, HIV, and Drug Resistance Unit, World
Health Organization.
http://wwwc.house.gov/international_relations/109/news042605 .htm
Written Testimony of William D. Moeller
President, American Biotech Laboratories
80 West Canyon Crest Road
Alpine, Utah 84004
Presented to Members of The House International Relations Committee
Subcommittee on Africa, Global Human Rights, and International Operations
April 26, 2005
INTRODUCTION
Good Morning. I am William D. Moeller, Chairman and President of American
Biotech Laboratories
of Alpine, Utah (ABL), a company which produces engineered, metallic
silver, nano-sized particles
in water-based products. Our engineered silver particles have performed far
beyond anyones
expectations as anti-microbial agents, against a staggering variety of
microbes such as malaria, flesheating
bacteria (MRSA Methicillin Resistant Staphylococcus aureus) and E.coli.
Whether used on surfaces as disinfectants or if taken internally as
supplements, all of our ABL products
are non-toxic and have no known adverse human side effects. Our products
have surprised many
experts in the medical and science worlds because of their ability to
combat bacteria, yeast, and viruses.
ABL products have been proven to destroy anthrax spores and bubonic plague
bacteria on surfaces, to
eliminate the malaria parasite in humans and a host of other beneficial
results.
We have developed five products to date as well as several other new
products currently in our product
development pipeline. We manufacture all of our products in the United
States. One product ASAPAGX-
32 (a water solution containing 32 ppm of our engineered silver
nano-particles) has already been
approved by the EPA as a surface disinfectant for hard, non-porous surfaces
in commercial, residential,
industrial, hospital and medical environments. Another product called
Silgel is a non-toxic
moisturizing gel, which utilizes our ASAP-AGX-32 as a raw material supply
of silver particles. It is
currently undergoing the final steps for FDA approval for the treatment of
lacerations, first and second
degree burns, abrasions, surgical wounds, skin ulcers etc. Several other
new ABL products will soon
warrant the filing of new FDA and/or USDA applications.
More.....
http://wwwc.house.gov/international_relations/109/moe042605. pdf
--
The Silver List is a moderated forum for discussing Colloidal Silver.
Instructions for unsubscribing are posted at: http://silverlist.org
To post, address your message to: silver-list@eskimo.com
Silver List archive: http://escribe.com/health/thesilverlist/index.html
Address Off-Topic messages to: silver-off-topic-l...@eskimo.com
OT Archive: http://escribe.com/health/silverofftopiclist/index.html
List maintainer: Mike Devour <mdev...@eskimo.com>
